Vimarsana
Biggest News Aggregation in the World

Hepatitis D News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hepatitis D. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hepatitis D Today - Breaking & Trending Today

Exploring the global health challenge of hepatitis D - Vimarsana News

Exploring the global health challenge of hepatitis D

Review explores the global impact of the hepatitis D virus (HDV) on public health, detailing its transmission, clinical course, diagnosis, and treatment options.

Promising Monoclonal Antibody for Treating Chronic Hepatitis B and D - Vimarsana News

Promising Monoclonal Antibody for Treating Chronic Hepatitis B and D

The effectiveness of the engineered investigational human monoclonal antibody VIR-3434 in inhibiting viral spread in hepatitis B and D viruses demonstrated.

World Hepatitis Day | Hepatitis D Is Zoonotic & Came From America: New Study Dismantles Everything We Knew About The Disease - Vimarsana News

World Hepatitis Day | Hepatitis D Is Zoonotic & Came From America: New Study Dismantles Everything We Knew About The Disease

New study reveals that Hepatitis D is zoonotic and came from America. This finding could help explain the sudden outbreak of the disease globally.

#VisualAbstract: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D - Vimarsana News

#VisualAbstract: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute

Buleviritide reduces viral load in patients with chronic hepatitis D - Vimarsana News

Buleviritide reduces viral load in patients with chronic hepatitis D

1. In this randomized controlled trial, 48 weeks of buleviritide treatment resulted in reduced hepatitis D ribonucleic acid (RNA) levels in patients with chronic hepatitis D. 2. The buleviritide group also had lower alanine transaminase (ALT) levels as compared to controls. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis D virus (HDV) is an RNA